Kim Sukjin, Oh Jeongjae, Kim Kiseok
Department of Ophthalmology, Saevit Eye Hospital, Goyangsi, Korea.
Open Ophthalmol J. 2016 Feb 4;10:1-4. doi: 10.2174/1874364101610010001. eCollection 2016.
The authors present a case of morphologic changes of drusen and drusenoid pigment epithelial detachment (DPED) after treating choroidal neovascularization (CNV) using ranibizumab in age-related macular degeneration (AMD). A 71-year-old woman has noticed mild visual acuity deterioration in the right eye for several months. She was presented with some drusen and DPED associated with CNV. This patient was given intravitreal injection of 0.5 mg of ranibizumab five times at monthly intervals for treating CNV. DPED in the temporal and drusen in the superior to macula were diminished, which continued up to 2 months. Intravitreal ranibizumab injection may have influenced with diminishment of drusen and DPED. After 2 months, CNV was recurred.
作者报告了1例年龄相关性黄斑变性（AMD）患者在使用雷珠单抗治疗脉络膜新生血管（CNV）后玻璃膜疣和类玻璃膜疣色素上皮脱离（DPED）的形态学变化。一名71岁女性数月来注意到右眼视力轻度下降。她被诊断为患有一些与CNV相关的玻璃膜疣和DPED。该患者每月接受1次玻璃体内注射0.5mg雷珠单抗，共5次，以治疗CNV。颞侧的DPED和黄斑上方的玻璃膜疣减少，这种情况持续了2个月。玻璃体内注射雷珠单抗可能对玻璃膜疣和DPED的减少有影响。2个月后，CNV复发。
